EU nod for MSD hep C therapy
European regulators have waved through Merck, Sharp & Dohme’s Zepatier bringing a new treatment option to patients with hepatitis C.
Read More
Tag: elbasvir
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
